Evidence map›Paper›PMID 39046510›Full record

ArticleAnnals of hematology2024

Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.

John Yan, M Bakri Hammami, John X Wei, Nishi Shah, Mendel Goldfinger, Ioannis Mantzaris, Noah Kornblum, Kira Gritsman, Alejandro Sica, Dennis Cooper and 8 more

Abstract read
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

John Yan *Department of Internal Medicine, Montefiore Medical Center, Bronx, NY, USA.
M Bakri Hammami *Department of Medicine, Jacobi Medical Center, Bronx, NY, USA.
John X WeiDepartment of Internal Medicine, Montefiore Medical Center, Bronx, NY, USA.
Nishi ShahDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Mendel GoldfingerDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Ioannis MantzarisDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Noah KornblumDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Kira GritsmanDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Alejandro SicaDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Dennis CooperDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Eric FeldmanDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Marina KonoplevaDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Kith PradhanDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Rahul ThakurDepartment of Medicine, Jacobi Medical Center, Bronx, NY, USA.
Charan VegivintiDepartment of Medicine, Jacobi Medical Center, Bronx, NY, USA.
Asma QasimDepartment of Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
Amit VermaDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA.
Swati GoelDepartment of Hematology/Oncology, Montefiore Medical Center, Bronx, NY, USA. Swgoel@montefiore.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of demographic characteristics and social determinants on cancer outcomes is widely recognized in various malignancies but remains understudied in myelofibrosis (MF). This study aims to investigate social and demographic variables associated with MF survival. We retrospectively reviewed data of biopsy-proven MF patients from the Surveillance, Epidemiology and End Results (SEER) database (2000-2021) and Montefiore Medical Center (2000-2023), an underserved inner-city hospital. The SEER cohort included 5,403 MF patients and was predominantly Non-Hispanic (NH) White (82%) with a median age of 69 years. The age-adjusted incidence rate of MF was 0.32 cases per 100,000 person-years, increasing annually by 1.3% from 2000 to 2021. Two- and five- year overall survival rates were 69% and 42%, respectively. Worse cause-specific survival was associated with older age, male sex, and diagnosis before 2011 (year of Ruxolitinib approval). NH-Black ethnicity, unmarried status and lower median income were independent predictors of worse overall survival. The single-center analysis included 84 cases, with a median age of 66 years. NH-White patients comprised 37% of the sample, followed by NH-Black (28.5%). Two- and five- year overall survival rates were 90% and 61%, respectively, with NH-Black patients exhibiting the lowest median survival, although the difference was not statistically significant. Age was a significant predictor of worse survival in this cohort. NH-Black and Hispanic patients lived in areas with higher socioeconomic and demographic stress compared to NH-White patients. Overall, this study highlights the association of social and demographic factors with MF survival and emphasizes the need for equitable healthcare and further exploration of social-demographic factors affecting MF survival.

Indexed as

Primary MyelofibrosisSEER ProgramAdultAgedAged, 80 and overDatabases, FactualFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesSocioeconomic FactorsSurvival RateUnited StatesEpidemiologyEthnicityMyelofibrosisMyeloproliferative neoplasmsSocial determinants of health

Identifiers

PMID39046510
PMCPMC11358356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.